Castle Biosciences (CSTL) Proxy filing summary

Executive summary

• Achieved $344 million in revenue for 2025, exceeding guidance, with 4% year-over-year growth and 37% increase in core test report volume, reflecting strong clinical adoption and operational execution.

• Maintained a robust balance sheet with $299.5 million in cash, cash equivalents, and marketable securities as of year-end 2025, supporting future growth initiatives.

• Continued focus on innovative diagnostic tests for dermatologic cancers, Barrett's esophagus, and uveal melanoma, supported by 158 peer-reviewed studies.

• Annual engagement with top 25 stockholders, representing 20% of shares, to discuss strategy, governance, compensation, and risk oversight.

Voting matters and shareholder proposals

• Election of three Class I directors to serve until the 2029 annual meeting.

• Ratification of KPMG LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory approval of executive compensation (Say-on-Pay).

• Approval of the updated non-employee director compensation policy.

Board of directors and corporate governance

• Board consists of eight members divided into three classes, with a mix of skills in diagnostics, healthcare, finance, and commercialization.

• 38% women and 13% underrepresented minorities on the board as of April 2026.

• All directors except the CEO are independent; 100% independent board committees.

• Annual board and committee self-assessments, robust stock ownership guidelines, and separation of chair and CEO roles.

• Classified board structure maintained for continuity and long-term focus.